Last reviewed · How we verify
Intravenous Bolus Furosemide
At a glance
| Generic name | Intravenous Bolus Furosemide |
|---|---|
| Also known as | Loop diuretic administration |
| Sponsor | Momentum Research, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers (PHASE1)
- Comparison of the Effectiveness of Different Diuretic Therapies in the Management of Acute Heart Failure (NA)
- Natriuresis-guided Depletion After Cardiac Surgery (NA)
- Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure (PHASE1)
- Loop Diuretic Therapy in Acutely Decompensated Heart Failure
- Effect of Giving Reduced Fluid in Children After Trauma (NA)
- Fluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery (NA)
- PuO2 in RenalGuard Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Bolus Furosemide CI brief — competitive landscape report
- Intravenous Bolus Furosemide updates RSS · CI watch RSS
- Momentum Research, Inc. portfolio CI